Catalyst Pharmaceutical
Partners, Inc. CPRX announced today that it has been advised by the
Department of Veterans Affairs Cooperative Studies Program (VACSP) that the
availability of top-line results from Catalyst's CPP-109 (vigabatrin) Phase
II(b) trial for cocaine addiction will be delayed. VACSP now expects to
provide the top-line results to the Company during the first half of November
2012. VACSP is the Company's collaborator responsible for the management and
statistical analyses of the data being collected from the trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in